CSL Limited trades at a decade-low P/E, despite ongoing revenue and profit growth, presenting significant upside potential. Learn more about CMXHF stock here.

Narrow-moat CSL reiterated fiscal 2025 guidance for constant-currency group net profit after tax before amortization, or NPATA, of USD 3.2 billion to USD 3.3 billion, implying 10%-13% growth on fiscal ...

Shares of the Australia-based CSL Ltd. (AU:CSL) fell by over 4% as of writing despite the company achieving higher profit in FY24. The company reported an NPAT (net profit after tax) attributable to ...

As investors, we’re irresistibly drawn to milestones, and the past year has provided a jackpot of them. The ASX stormed past 8,000, Bitcoin soared beyond US$100,000, NVIDIA hit a mind-boggling US$3 ...

ADRs of CSL Limited (OTCQX:CSLLY) dropped ~16% on Tuesday as Wall Street reacted to Australian biotech’s plans to lay off 15% of its workforce, announced in conjunction with its fiscal 2025 financials ...

CSL Ltd. is a biopharmaceutical company, which engages in the manufacture, marketing, and distribution of biopharmaceutical and allied products. It operates through the following segments: CSL Behring ...

This biotech giant could have major upside potential in 2026. The post A once-in-a-decade opportunity to buy CSL shares? appeared first on The Motley Fool Australia.

Narrow-moat CSL reported fiscal 2024 revenue of USD 14.8 billion and net profit after tax before amortization of USD 2.9 billion, up 11% and 15% in constant currency, respectively, close to our ...